Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health
Geriatric HIV: living with multiple medical conditions will become the norm as population ages
Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation
Patients with HIV can safely receive kidneys from deceased HIV-positive donors, with good five-year survival rates
Tenofovir HIV PrEP causes no long-term harm to kidneys
Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment
Heart attack link to abacavir persists in D:A:D study
